Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of China Resources Pharmaceutical Group Limited (the "**Company**") hereby announces that, with effect from 18 June 2025, Mr. Wang Yuhang ("**Mr. Wang**") has been appointed as a non-executive Director.

Mr. Wang Yuhang, aged 52, is an external director of business units of China Resources (Holdings) Company Limited ("**China Resources Group**"). He served as the Vice President and Deputy General Manager of Environmental Health and Safety Department of China Resources Group from January 2015 to July 2024 and subsequently the Deputy General Manager of China Resources Chemical Innovative Materials Co., Ltd. from August 2024 to May 2025. Before joining China Resources Group, Mr. Wang served as the Deputy Director of Ionization Chamber of Beijing Department of Environmental Protection Radiation Environmental Research Center from April 1999 to May 2001; Manager of Consulting Department of Beijing Bona Baijia Cultural Development Co., Ltd from May 2001 to March 2002; the Deputy Director of Institute of Safety Management and Technology, Director of Registration Management Centre for Certified Safety Engineers and Director of Institute of Safety Production Theory and Regulatory Standards of China Academy of Safety Science and Technology during the periods from April 2002 to January 2009 and from August 2012 to January 2015; and Deputy Director of Security Office and General Manager of Safety and Environmental Department of China Agri-Industries Holdings Limited from January 2009 to August 2012.

Mr. Wang obtained a Bachelor's degree of Chemistry Education from Anqing Normal University, Anhui Province in July 1995, and a Master's degree of Environmental Engineering from Beijing Institute of Technology in February 1999.

There is no service contract entered into between Mr. Wang and the Company for his position as a non-executive Director. Mr. Wang shall hold office until the next annual general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Wang shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Wang will not receive any Director's emolument from the Company.

As at the date of this announcement, Mr. Wang does not have any interests in the shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Wang has confirmed that (i) he has and had no any other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment that should be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board takes this opportunity to extend a warm welcome to Mr. Wang for his appointment.

By Order of the Board
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 18 June 2025

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.